Zhao P, Zhao L J, Cao J, Hong H Y, Qi Z T
Department of Microbiology, Second Military Medical University, Shanghai 200433, China.
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002 May;34(3):341-6.
The human interleukin-2 signal peptide and a potent universal helper T lymphocyte epitope PADRE were spliced to the 5' terminus of hepatitis B viru score HBcAg gene. The modified HBcAg gene was used to construct a DNA vaccine. After the resulted DNA vaccine construct was transfected into COS7 cells, secreted HBcAg was detected in the supernatant by ELISA. BALB/c mice were vaccinated intramuscularly with the modified HBcAg DNA vaccine and the wild-type one. Serum antibodies,T lymphocyte proliferative response and cytotoxic T lymphocyte response of the immunized mice were measured. The results showed that the modified DNA construct induced cellular and humoral immune responses much stronger in vivo than the natural one did, indicating the potential value as a therapeutic vaccine for treatment of chronic hepatitis B.
将人白细胞介素-2信号肽和一种强效通用辅助性T淋巴细胞表位PADRE剪接到乙肝病毒核心抗原（HBcAg）基因的5'末端。使用修饰后的HBcAg基因构建DNA疫苗。将所得的DNA疫苗构建体转染到COS7细胞中后，通过ELISA在上清液中检测到分泌的HBcAg。用修饰后的HBcAg DNA疫苗和野生型疫苗对BALB/c小鼠进行肌肉注射免疫。检测免疫小鼠的血清抗体、T淋巴细胞增殖反应和细胞毒性T淋巴细胞反应。结果表明，修饰后的DNA构建体在体内诱导的细胞免疫和体液免疫反应比天然构建体更强，表明其作为治疗慢性乙型肝炎的治疗性疫苗具有潜在价值。
